Cardiovascular Health, Lifestyle Factors, and Social Determinants in Asian Subpopulations in the United States
Asian Americans are the fastest-growing population in the United States (US).1 Although Asian adults represent a highly heterogeneous population comprised of diverse groups (e.g., Chinese, Asian Indian, Filipino adults) — each with its own demographic, socioeconomic, and cultural characteristics—they are frequently categorized into a single group (“Asian”) for public health surveillance efforts.2,3 However, emerging evidence suggests that the aggregation of Asian adults may conceal important differences in the health status of unique groups that comprise this population. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 16, 2024 Category: Cardiology Authors: Sudheesha Perera, ZhaoNian Zheng, Rishi Wadhera Source Type: research
The End of a Controversy: The Rise, Fall, and Redemption of Paclitaxel-Coated Devices
Paclitaxel-coated devices (PCDs) for peripheral revascularization were initially considered one of the great success stories in endovascular treatment. Supported by more than a half dozen randomized trials, PCDs promised prolonged patency and decreased rates of target-lesion revascularization that had not been observed with non-coated devices.1,2 Once approved in the United States (US), PCDs became the most frequently used devices for femoropopliteal artery treatment and had a Class I indication in US guidelines. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 16, 2024 Category: Cardiology Authors: Eric A. Secemsky, Robert W. Yeh, Peter A. Schneider, William Gray, Sahil Parikh Tags: Editorial Source Type: research
Assessing the Role of Bempedoic Acid in Lipid-Lowering Therapy
We read with interest the study by Cordero et al. presenting their results1 of an intention-to-treat meta-analysis of the 4 CLEAR trials. Their study aims to consolidate the results of the CLEAR Outcomes trial. In that trial, bempedoic acid (BPA) proved to reduce a four-component major adverse cardiovascular event (MACE) endpoint, that included cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization, as well as fatal and non-fatal MI and coronary revascularization. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 16, 2024 Category: Cardiology Authors: David Fernandez-Vazquez, Sarah Weideman, Subhash Banerjee Source Type: research
The End of a Controversy: The Rise, Fall and Redemption of Paclitaxel-Coated Devices
Paclitaxel-coated devices (PCDs) for peripheral revascularization were initially considered one of the great success stories in endovascular treatment. Supported by more than a half dozen randomized trials, PCDs promised prolonged patency and decreased rates of target-lesion revascularization that had not been observed with non-coated devices(1,2). Once approved in the US, PCDs became the most frequently used devices for femoropopliteal artery treatment and had a Class I indication in US guidelines(3-5). (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 16, 2024 Category: Cardiology Authors: Eric A. Secemsky, Robert W. Yeh, Peter A. Schneider, William Gray, Sahil Parikh Tags: Editorial Source Type: research
Cardiovascular Health, Lifestyle Factors, and Social Determinants Among Asian Sub-Populations in the US
Asian Americans are the fastest growing population in the United States.1 Although Asian adults represent a highly heterogenous population comprised of diverse groups (e.g., Chinese, Asian Indian, Filipino adults) - each with its own demographic, socioeconomic, and cultural characteristics - they are frequently categorized into a single group ( “Asian”) for public health surveillance efforts.2,3 However, emerging evidence suggests that the aggregation of Asian adults may conceal important differences in the health status of unique groups that comprise this population. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 16, 2024 Category: Cardiology Authors: Sudheesha Perera, ZhaoNian Zheng, Rishi Wadhera Source Type: research
Corrigendum to ‘Effects of Diet on 10-Year Atherosclerotic Cardiovascular Disease Risk (from the DASH Trial)’ [American Journal of Cardiology 187 (2023) 10-17]
“The authors regret that the P-values accompanying Figure 2 were incorrect. During a recent review, the authors identified a potential inconsistency in their approach to using three-way interaction terms to test for differences across strata. In the original publication, the approach incorporated both the two-way and 3-way interaction terms. However, this was suboptimal, and a more direct comparison should focus on the P-value from the three-way interaction alone. While all the stratified results are correct, we revised the P-values to better reflect the comparison of the point estimates acr oss strata. (Source: The Amer...
Source: The American Journal of Cardiology - February 12, 2024 Category: Cardiology Authors: Sun Young Jeong, Christina C. Wee, Lara C. Kovell, Timothy B. Plante, Edgar R. Miller, Lawrence J. Appel, Kenneth J. Mukamal, Stephen P. Juraschek Tags: Corrigendum Source Type: research
Corrigendum to ’Effects of Diet on 10-Year Atherosclerotic Cardiovascular Disease Risk (from the DASH Trial)’ [American Journal of Cardiology 187 (2023) 10-17]
“The authors regret that the P-values accompanying Figure 2 were incorrect. During a recent review, the authors identified a potential inconsistency in their approach to using three-way interaction terms to test for differences across strata. In the original publication, the approach incorporated both the two-way and 3-way interaction terms. However, this was suboptimal, and a more direct comparison should focus on the P-value from the three-way interaction alone. While all the stratified results are correct, we revised the P-values to better reflect the comparison of the point estimates acr oss strata. (Source: The Amer...
Source: The American Journal of Cardiology - February 12, 2024 Category: Cardiology Authors: Sun Young Jeong, Christina C. Wee, Lara C. Kovell, Timothy B. Plante, Edgar R. Miller, Lawrence J. Appel, Kenneth J. Mukamal, Stephen P. Juraschek Tags: Corrigendum Source Type: research
Long-Term Percutaneous Coronary Intervention Outcomes in Chronic Versus Acute Coronary Syndromes (TARGET All Comers Trial)
Drug-eluting stents (DESs) use a polymer to fix and modulate the elution of cytotoxic drugs, with the aim of preventing in-stent restenosis. The persistence of the polymer after drug elution can result in delayed arterial healing and subsequently late stent thrombosis and in-stent restenosis.1,2 This led to the development of biocompatible durable and biodegradable polymers. The latter gradually loses its polymer after drug elution to leave a bare-metal stent in situ and is the fundamental premise for developing biodegradable polymer (BP) DESs. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 11, 2024 Category: Cardiology Authors: Kush P. Patel, Alexandra J. Lansky, Henning Kelb æk, Bo Xu, Niels van Royen, Thomas W. Johnson, Richard Anderson, William Wijns, Andreas Baumbach, TARGET AC investigators Source Type: research
Long-term PCI Outcomes in Chronic Versus Acute Coronary Syndromes (TARGET All Comers Trial)
Drug-eluting stents (DES) use a polymer to fix and modulate the elution of cytotoxic drugs with the aim of preventing in-stent restenosis. Persistence of the polymer after drug elution can result in delayed arterial healing and subsequently late stent thrombosis and in-stent restenosis 1,2. This led to the development of biocompatible durable and biodegradable polymers. The latter gradually loses its polymer after drug elution to leave a bare metal stent in-situ and is the fundamental premise for developing biodegradable polymer (BP) DES. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 11, 2024 Category: Cardiology Authors: Kush P. Patel, Alexandra J. Lansky, Henning Kelb æk, Bo Xu, Niels van Royen, Thomas W. Johnson, Richard Anderson, William Wijns, Andreas Baumbach, TARGET AC Investigators Source Type: research
Transcatheter Aortic Valve Implantation in a Patient With Anomalous Left Main Coronary Artery from Right Coronary Artery
In this study, we present the case of successful TAVI in a 78-year-old patient with anomalous left main coronary artery originating from the right coronary artery. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 7, 2024 Category: Cardiology Authors: Sivakumar Sudhakaran, Parijat Joy, Alex Sbrocchi, Robert Hebeler, Robert Stoler Source Type: research
Electrocardiograms Do Not Detect Myocardial Ischemia in Patients With Williams Syndrome and Nonsyndromic Elastin Arteriopathy With Coronary Artery Stenosis
Coronary artery stenosis (CAS) may affect up to 27% of patients with Williams syndrome (WS), which may lead to myocardial ischemia. Patients with WS face a 25- to 100-fold greater risk of sudden cardiac death, frequently linked to anesthesia. Assessing CAS requires either imaging while under general anesthesia or intraoperative assessment, with the latter considered the gold standard. Our study aimed to identify electrocardiogram (ECG) markers of myocardial ischemia in patients with WS or nonsyndromic elastin arteriopathy and documented CAS. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 7, 2024 Category: Cardiology Authors: Claudia Algaze, Henry Chubb, Anna M. Deitch, Thomas Collins Source Type: research
A Ten-Year Follow-Up Study of the Association Between Uric Acid and Adverse Cardiovascular Events in Patients With Coronary Artery Disease
The association between uric acid (UA) and long-term mortality in patients with coronary artery disease is poorly investigated. We assessed the association between UA and 10-year mortality after percutaneous coronary intervention (PCI) in 3,998 patients who underwent PCI. Patients were categorized in groups according to UA tertiles: tertile 1 (UA7.94 mg/100 ml, n = 1,311). The primary outcome was 10-year all-cause mortality. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 6, 2024 Category: Cardiology Authors: Gjin Ndrepepa, Sebastian Kufner, Salvatore Cassese, Michael Joner, Erion Xhepa, Jens Wiebe, Hendrik B. Sager, Thorsten Kessler, Karl-Ludwig Laugwitz, Heribert Schunkert, Adnan Kastrati Source Type: research
Association of Beta-Blocker Use With Exercise Capacity in Participants With Heart Failure With Preserved Ejection Fraction: A Post Hoc Analysis of the RELAX Trial
Patients with heart failure with preserved ejection fraction (HFpEF) often receive β-blocker (BB) therapy for management of co-morbidities. However, the association of BB therapy with exercise capacity and health-related quality of life (HRQL) in HFpEF is not well-studied. In this post hoc analysis of the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capa city in HFpEF (RELAX) trial, which included patients with chronic stable HFpEF with peak exercise capacity assessment at baseline and at 12 and 24 weeks of follow-up, we evaluated the association of BB use with the measures of exercise capacity (...
Source: The American Journal of Cardiology - February 6, 2024 Category: Cardiology Authors: Lajjaben Patel, Matthew W. Segar, Neil Keshvani, Vinayak Subramanian, Ambarish Pandey, Alvin Chandra Source Type: research
Association of Beta Blocker Use with Exercise Capacity in Participants with Heart Failure with Preserved Ejection Fraction: A Post-Hoc Analysis of the RELAX Trial
Patients with heart failure with preserved ejection fraction (HFpEF) often receive beta-blocker (BB) therapy for management of co-morbidities. However, the association of BB therapy with exercise capacity and health related quality-of-life (HRQL) in HFpEF is not well-studied. In this post-hoc analysis of the RELAX trial, which included chronic stable patients with HFpEF with peak exercise capacity assessment at baseline, 12 weeks, and 24 weeks follow-up, we evaluated the association of BB use with measures of exercise capacity (peak exercise oxygen uptake, VO2peak), anaerobic threshold (VO2AT), and HRQL (Minnesota Living w...
Source: The American Journal of Cardiology - February 6, 2024 Category: Cardiology Authors: Lajjaben Patel, Matthew W Segar, Neil Keshvani, Vinayak Subramanian, Ambarish Pandey, Alvin Chandra Source Type: research
A 10-year Follow-up Study of Association Between Uric Acid and Adverse Cardiovascular Events in Patients With Coronary Artery Disease
The association between uric acid (UA) and long-term mortality in patients with coronary artery disease (CAD) is poorly investigated. We assessed the association between UA and 10-year mortality after percutaneous coronary intervention (PCI) in 3998 patients undergoing PCI. Patients were categorized in groups according to UA tertiles: tertile 1 (UA7.94 mg/dl; n=1311). The primary outcome was 10-year all-cause mortality. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 6, 2024 Category: Cardiology Authors: Gjin Ndrepepa, Sebastian Kufner, Salvatore Cassese, Michael Joner, Erion Xhepa, Jens Wiebe, Hendrik B. Sager, Thorsten Kessler, Karl-Ludwig Laugwitz, Heribert Schunkert, Adnan Kastrati Source Type: research
